Format:
26
ISSN:
1756-8927
Content:
Histone deacetylase 8 (HDAC8), a unique class I zinc-dependent HDAC, is an emerging target in cancer and other diseases. Its substrate repertoire extends beyond histones to many nonhistone proteins. Besides being a deacetylase, HDAC8 also mediates signaling via scaffolding functions. Aberrant expression or deregulated interactions with transcription factors are critical in HDAC8-dependent cancers. Many potent HDAC8-selective inhibitors with cellular activity and anticancer effects have been reported. We present HDAC8 as a druggable target and discuss inhibitors of different chemical scaffolds with cellular effects. Furthermore, we review HDAC8 activators that revert activity of mutant enzymes. Isotype-selective HDAC8 targeting in patients with HDAC8-relevant cancers is challenging, however, is promising to avoid adverse side effects as observed with pan-HDAC inhibitors.
Note:
Gesehen am 06.02.2018
In:
Future medicinal chemistry, London : Future Science, 2009, 8(2016), 13, Seite 1609-1634, 1756-8927
In:
volume:8
In:
year:2016
In:
number:13
In:
pages:1609-1634
In:
extent:26
Language:
English
DOI:
10.4155/fmc-2016-0117
Bookmarklink